Mineralys Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for hypertension and its related comorbidities, such as chronic kidney disease (CKD) and obstructive sleep apnea (OSA). The company's lead product candidate, lorundrostat, is a highly selective aldosterone synthase inhibitor designed to address medical needs in these areas. With a mission to improve patient outcomes, Mineralys operates fully remotely and fosters a collaborative environment that values scientific excellence and innovation. Headquartered in Radnor, Pennsylvania, Mineralys is committed to utilizing cutting-edge science to combat diseases related to dysregulated aldosterone.